Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with a poor prognosis and one for which immunotherapy remains a viable option. Experimental tumor models have shown that regulatory T cells, a functionally unique subset of T cells, can suppress effective antitumor immune responses. This suppression might explain the poor outcome of some of the immunotherapy protocols currently being used. A better understanding of the role of regulatory T cells in HCC is important for design of future immunotherapy-based clinical protocols. We have studied regulatory T cells from 84 patients with HCC and 74 controls, including healthy donors, patients with chronic hepatitis B virus and hepatitis C virus infection and nonviral liver cirrhosis. Regulatory 
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide (1) with a poor prognosis and limited survival in the majority of patients. Current treatment options include surgical resection, liver transplantation (2) , and local ablative therapy, which are effective only in localized tumors (3) . Therefore, identifying and establishing alternative approaches for treatment of HCC is quiet a challenge and of high interest.
One approach that has shown promising results in other tumors is immunotherapy (4) . Also in HCC, several different studies suggest that immunotherapeutic approaches will be successful for the treatment of this disease. Lymphocytic infiltration of the tumors is indicative of a better survival after surgical resection of the tumors (5) . Adjuvant treatment with activated lymphocytes has also been shown to increase tumor-free survival after removal of the tumor (6) and first clinical trials using dendritic cells have been initiated (7, 8) .
In addition, recently, we have shown tumor-specific cellular and humoral immune responses against NY-ESO-1 in HCC patients (9) . Interestingly, we have found that >50% of HCC patients develop tumor-specific immune responses. However, in most patients analyzed, tumors progressed in spite of a tumor-specific humoral and cellular immune response. Therefore, we decided to analyze possible mechanisms, which might impact the potency of these tumor-specific immune responses in patients with HCC. CD4 + CD25 + regulatory T cells have been shown to play a critical role in immunologic self-tolerance as well as antitumor immune responses and transplantation (10, 11) . CD4 + CD25 + -positive regulatory T cells represent 5% to 10% of human CD4 + T cells, are anergic, and do not proliferate on T-cell receptor stimulation in vitro (12) . However, they can suppress the activation and proliferation of other CD4 + and CD8 + T cells (13, 14) . Experimental tumor models have shown that removal of CD25 + T cells changes the immune response to tumors both in vitro and in vivo (15) . Depletion of CD25 + T cells in mice resulted in a lower incidence or slower growth of B16 melanoma (16) . Recently, the regulatory function of regulatory T cells on concomitant tumor immunity was further shown by Turk et al., who were able to show that depletion of regulatory T cells by either cyclophosphamide treatment or depletion of GITR + cells resulted in a potent tumor-specific immune response in mice (17) . In addition, it has been shown that regulatory T cells can impair induction of both antigenspecific and nonspecific T cells in autologous lymphocytes in melanoma patients (18, 19) and predict reduced survival in ovarian cancer patients (20) .
Currently, no information on the role of regulatory T cells and their mechanism in HCC is available. Considering the importance of regulatory T cells in inhibiting effective antitumor immune responses, we studied these T cells in HCC patients. We analyzed peripheral blood from 84 HCC patients and compared the frequency of CD4 + CD25
+ T cells in these samples to patients with chronic hepatitis B virus (HBV)/hepatitis C virus (HCV) infection, healthy donors, and patients with nonviral liver cirrhosis. In addition, we assessed the proliferative and suppressive ability of CD4 
Materials and Methods
Patients and Healthy Donors. Blood samples were collected from a total of 84 HCC patients seen at the Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School (Hannover, Germany). HCC was diagnosed according to the diagnostic guidelines of the European Association for the Study of the Liver (21) . Written consent was obtained from all patients before blood, ascites, and tumor sampling and the Ethics Committee of Hannover Medical School approved the study protocol. Blood samples were also taken from healthy volunteers, patients with chronic viral infection (HBV/HCV, with no evidence of cirrhosis and no antiviral therapy) and nonviral liver cirrhosis without a tumor. Patient characteristics and disease classification are shown in Tables 1 and 2 .
Cell Isolation and Sorting. Peripheral blood mononuclear cells (PBMC) were isolated from freshly obtained blood by Ficoll density gradient (Biochrom, Berlin, Germany) as described before (22 
CD25
+ and CD4 + CD25 À cells using the BD FACSAria cell sorting system (Becton Dickinson, Heidelberg, Germany). The purity of the cells after sorting was 98% to 99%. Ascites was collected at the time of paracentesis. The fluid was centrifuged at 1,200 rpm for 10 minutes and the cell pellet was separated on a Ficoll density gradient as described previously (23) . The lymphocyte layer was collected, washed, and further stained for regulatory T cells as described. Flow Cytometric Analysis. To determine the frequency and phenotype of regulatory T cells in PBMCs, TILs, and ascites, multicolor fluorescenceactivated cell sorting analysis was done using the following antibodies: anti-CD4, anti-CD25, anti-HLA-DR, anti-CD45RA, anti-CD45RO, anti-CD152 (BD PharMingen, Heidelberg, Germany), and anti-GITR (R&D Systems, Weisbaden, Germany). Flow cytometry was done on a Becton Dickinson FACSCalibur using CellQuest software. Isotype-matched antibodies were used with all the samples as controls. Isolation of TILs. Tumor specimens were collected at the time of surgery and processed by cutting into small pieces and incubated in complete medium for 2 hours to obtain single cell suspensions. Resulting cells were washed twice in PBS and lymphocytes were isolated by Ficoll density gradient as described. CD4 + CD25
+ regulatory T cells were isolated as described above. ELISA. Culture supernatants from the proliferation assays were removed before addition of [ 3 H]thymidine and tested for IFN-g (Quantikine ELISA kit) or IL-10 (Immunotools, Friesoythe, Germany) production according to the manufacturer's instructions.
Analysis of Foxp3 Expression by Real-time PCR. CD4 + CD25 À and CD4 + CD25 + cells were sorted as described above. RNA was isolated from both cell populations using the RNeasy kit (Qiagen, Hilden, Germany). cDNA was generated by SuperScript reverse transcriptase using oligo(dT) (Invitrogen Life Technologies, Karlsruhe, Germany). Transcript levels of Foxp3 and glyceraldehyde-3-phosphate dehydrogenase were quantified using real-time quantitative PCR and SYBR Green dye (iCycler iQ, Bio-Rad, Munich, Germany) using the following primers: Foxp3 forward 5V -CTACGCCACGCTCATCCGCTGG-3V and reverse 5V -GTAGGGTTGGAA-CACCTGCTGGG-3Vand glyceraldehyde-3-phosphate dehydrogenase forward 5V -GAAGGTGAAGGTCGGAGTC-3V and reverse 5V -GAAGATGGTGATGG-GATTTC-3V . Target cDNA was quantified using the delta-delta-CT method (24) . Results are shown as relative Foxp3 mRNA levels.
Western Blot Analysis. CD4 + T cells were purified from freshly isolated PBMC of HCC patients and healthy controls. Nuclear extracts were prepared as described previously (25) and run on a 10% SDS gel. Foxp3 protein was detected using a polyclonal anti-Foxp3 antibody (Abcam, Cambridge, United Kingdom).
Statistical Analysis. Data are expressed as mean F SE for percentages. Statistical analysis was done using Student's t test to assess differences between the different study groups. P < 0.01 was considered statistically significant.
Results

HCC Patients Have Increased Numbers of CD4
+ + CD25 + + T Cells in Their Peripheral Blood. We analyzed peripheral blood of 84 patients with HCC, 19 patients with chronic HCV infection, 17 patients with chronic HBV infection, 21 healthy donors, and 13 (Fig. 1A) . Individual frequencies of CD4 + CD25 high cells as well as the cumulative data for all the patients and healthy donors analyzed are represented as scatter plots (Fig. 1B) . As shown, the frequency of CD4 + CD25 high T cells in HCC patients was significantly higher in HCC patients (3.92 F 3.3%) than in healthy donors (1.17 F 0.87%), HBV (1.06 F 0.68%), HCV (0.70 F 0.45%), and liver cirrhosis (0.78 F 0.43%) patients. The number of CD4 + CD25 + T cells in HCC patients did not change depending on the presence of liver cirrhosis or hepatitis infection (data not shown). These numbers also did not correlate with stage of the disease. Thus, the prevalence of
+ cells in HCC patients was significantly higher (P < 0.001) than in healthy donors or patients with (P < 0.01) viral hepatitis. + cells from HCC patients and healthy donors also confirmed the expression of Foxp3 in nuclear extracts (Fig. 2C) . Overall, our data show that a high frequency of circulating CD4 + CD25
+ cells from HCC patients express GITR, CD45RO, CTLA-4, HLA-DR, and Foxp3 mRNA. These characteristics are highly indicative of regulatory CD4 + CD25 + T cells already described in both healthy donors and cancer patients (26, 30) . Therefore, the CD4 + T cells mainly produce IL-10 (which is a cytokine known to inhibit T-cell proliferation) and very low levels of IFN-g. Similarly, both cell populations from healthy donors (n = 11) and patients with chronic HCV infection (n = 5) had the same cytokine profile (Fig. 3) . , and CD4 + CD25 À populations were separated using additional surface markers, such as HLA-DR and CD45RA (see Fig. 2A) . B, percentage of CD4 + CD25 high cells in the peripheral blood of HCC (n = 84), healthy (n = 21), HCV (n = 19), HBV (n = 17), and nonviral liver cirrhosis (n = 13) patients. Individual frequencies for every patient analyzed are shown. CD4 + CD25 high cells are presented as a percentage of total CD4 + cells. Prevalence of regulatory T cells in HCC patients was significantly higher than in healthy controls (P < 0.001) or patients with HBV/HCV infection (P < 0.01). (Fig. 4B) . The supernatants from the proliferation cultures were analyzed for IFN-g secretion by ELISA, which showed that whenever the proliferation was inhibited the secretion of IFN-g also decreased in parallel. These data suggest that CD4 + CD25 + T cells from HCC patients can also inhibit cytokine secretion and proliferation of autologous CD4 + CD25 À cells on T-cell receptor stimulation. CD4 + + CD25 + + Suppression Is Mediated through a Cell Contact Mechanism. Several studies have shown that mechanism of action of CD4 + CD25 + regulatory T cells is mainly cell contact dependent (31) (32) (33) . However, role of cytokines, such as IL-10 and transforming growth factor-h, in the suppressive ability of regulatory T cells has also been shown (33) (34) (35) T cells in TILs of HCC patients and compared them with regulatory T cells in their peripheral blood by flow cytometry (Fig. 6A) . Tumors from five HCC patients were analyzed for regulatory T cells in TILs. The frequency of CD4 + CD25 high cells in TIL of HCC patients was similar to the peripheral blood with an average of 6.55 F 3.5 of CD4 + cells for TIL and 1.84 F 1.06 for peripheral blood (Fig. 6A) . Ascites that is present within the vicinity and drainage of the tumor might very likely represent the milieu of the tumor environment (36) . We determined the prevalence of CD4 + CD25 + regulatory T cells also in ascites of HCC patients and compared them with regulatory T cells in their peripheral blood. There was also an increase in prevalence of regulatory T cells in ascites and this increase was similar and comparable with the increase seen in the peripheral blood of the patient. The CD4 + CD25 + frequency in ascites of the HCC patients was found to be 7.2 F 2.7% compared with the peripheral blood, which was 6.0 F 3.7% (Fig. 6B) . These data showed that regulatory T-cell frequencies were increased not only in peripheral blood but also in ascites and TILs, suggesting that these T cells might suppress immune activation at the tumor site. CD4 + CD25 + T cells from TILs and ascites were further analyzed for expression of cell surface markers, such as HLA-DR and GITR, and a similar pattern as seen in peripheral blood of these patients was found ( Fig. 6C and D) . GITR expression on CD4 + CD25 + regulatory T cells in both tumor and peripheral blood was f68% and 46%, respectively. HLA-DR expression was also similar in both (65% for tumors and 62% for blood). Similar pattern was observed in ascites (Fig. 6D) . Expression of Foxp3 was also found in CD4 + CD25
Regulatory T Cells in HCC
+ purified from TILs (Fig. 6E) , reconfirming that the regulatory T cells were present in TILs of HCC patients. Our results suggest that in the tumor microenvironment as well as the peripheral blood of HCC patients there is a significant increase in the number of CD4 + CD25 + T cells.
Discussion
This study presents evidence for increase in frequency of CD4 + CD25
+ regulatory T cells in peripheral blood as well as tumor microenvironment of HCC patients. Eighty-four HCC patients were compared with healthy donors and patients with other liver diseases but no liver malignancies.
We used several cell surface markers to distinguish CD4 + CD25 + regulatory T cells from activated cells. Although CD25 is the typical cell surface marker used to identify regulatory T cells, its specificity is not limited to regulatory T cells but also to other types of activated T cells. Therefore, we decided to include other, more specific surface markers, such as GITR, HLA-DR, CD45RO, CD152, and CD45RA, to identify regulatory T cells by flow cytometry (26, 27) . This allowed for distinguishing T cells with regulatory properties from other activated CD4 + T cells in peripheral blood À and CD4 + CD25 + populations, stimulated with anti-CD3 and anti-CD28, and tested for their ability to proliferate either alone or in cocultures with increasing concentrations of CD4 + CD25 + cells as described in Materials and Methods. After 72 hours, 3 H was added to the cultures to measure proliferation. Data are representative of 9 HCC patients and 11 healthy donors. Proliferation was determined in triplicate cultures by 3 H incorporation. B, supernatants from the proliferation assay in A were removed after 24 hours and measured for secretion of IFN-g production by ELISA. Data are representative of 9 HCC patients and 11 healthy donors.
from HCC patients and controls. The stringent conditions used in our study led to sorting out a smaller population of CD4 + CD25 high cells in peripheral blood of HCC patients was significantly higher in peripheral blood from patients with HCC than in healthy controls or patients with HBV/HCV infection. Our data show no significant differences in the number of regulatory T cells between healthy controls and patients with chronic HCV/HBV infection and therefore confirms data shown previously by others Cancer Research (39). One study has shown an increase of CD4 + CD25 + cells in patients with HCV infection; however, in this study, less stringent criteria were used to identify Tregs and activated CD4 + T cells were not excluded (40) .
In ex vivo assays, we also studied the function of regulatory T cells in HCC patients by analyzing their proliferative and suppressive abilities as well as cytokine profile. + regulatory T cells isolated from HCC tumors were HLA-DR positive and GITR positive and also expressed Foxp3. Our data clearly showed that regulatory T-cell frequencies were increased not only in peripheral blood but also in ascites and in the tumor, suggesting that these T cells might suppress immune activation at the tumor site. Thus, the CD4 + CD25
+ T cells found in the TILs in HCC patients are clearly regulatory T cells and might play a role in hampering antitumor immune responses.
Recently, several studies have reported an increase in number of regulatory T cells in patients with different cancers (20, 23, 43, 44) . Several experimental models have shown that elimination of CD4 + CD25 + cells can lead to effective antitumor immune responses. In mice, treatment with anti-CD25 monoclonal antibody led to regression of leukemia and fibrosarcoma (45) . In another study, depletion of regulatory T cells resulted in a slower growth of B16 melanoma (16, 17) . These studies combined with our data suggest that Tregs in human cancer might suppress tumor-specific immune responses.
In addition, we have started to analyze the influence of current treatment options for HCC on Treg frequencies. Our preliminary data suggest that elevated numbers of regulatory T cells drop after removal of HCC tumors, suggesting a clear dependency of an increase in the frequency of regulatory T cells and occurrence of HCC. Due to the low frequency of tumorspecific CD4 + T cells in HCC as described by us previously (9), analysis of the antigen specificity by classic MHC peptide tetramers (46) or cytokine secretion analysis has not been feasible. However, work is in progress to address antigen and tumor specificity of regulatory T cells in HCC patients.
Our data at this point do not provide any mechanistic explanation for role of regulatory T cells in HCC patients. It remains to be shown as to how the increase in regulatory T cells contributes to immune tolerance or inhibition of effective antitumor immune responses in HCC. It is possible that the presence of regulatory T cells at the tumor site promote the tumor growth. On the other hand, secretion of inhibitory factors by tumors might cause expansion of regulatory T cells.
In summary, our data suggest that in HCC patients there is an increase of regulatory T cells in peripheral blood and tumor microenvironment. These T cells might prevent affective antitumor immune responses, and in designing immunotherapy protocols for HCC, regulatory T cells are one more obstacle to overcome. These findings will prove to be important for design of immunotherapeutic approaches to HCC.
